Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8 T-Cell Function.
JournalOpen Forum Infectious Diseases
PublisherOxford University Press
MetadataShow full item record
AbstractTo identify immunologic correlates of hepatitis C virus (HCV) relapse after direct-acting antiviral (DAA) therapy, we quantified select immune transcripts in whole blood from noncirrhotic HCV subjects treated with 4-6 weeks of DAAs. We identified specific markers of natural killer-cell and CD8+ T-cell function (GZMB, PRF1, NKp46) with higher expression in subjects who relapsed. These findings suggest a role for host immunity in HCV eradication with ultrashort DAA therapy. We quantified whole blood immune transcripts in noncirrhotic HCV subjects treated with shortcourse antiviral therapy. Markers of natural killer-cell and CD8+ T-cell function had higher expression in virologic relapsers, suggesting a role for host immunity in HCV eradication.
Rights/Terms© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Keyworddirect acting antiviral
gene expression analysis
hepatitis C virus
sustained virologic response
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15621